Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(1)
COMBINATION_PRODUCT(1)
2 unique interventions2 categories

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Terminated1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT03722108Phase 1/2Terminated
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
PrincipalinvestigatorStart date: 2019-02-07

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Institut du Cancer Montpellier

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Arthur Blackstock

Wake Forest University Health Sciences

Moderately Similar
3 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
Similarity Score30%

Maria Mazurkiewicz, Professor

Department of Oncology, Medical University of Lublin, Lublin Oncology Center

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Agnieszka Fronczek, MD

Department of Clinical Pathomorphology, Medical University of Lublin

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Yan Sun, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
4 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Vincent Chung

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Witold Zgodziński, MD, PhD

Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Anna Brzozowska, MD, PhD

Department of Oncology, Medical University of Lublin, Lublin Oncology Center

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Andrzej Dąbrowski, Professor

Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin

Related
1 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Andreas Kaubisch

Montefiore Medical Center

Related
2 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Allyson Ocean

Montefiore Medical Center

Related
3 trials

Shared therapeutic areas:

Adenocarcinoma of the Gastroesophageal Junction
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT03722108Phase 1/2PrincipalInvestigator

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
Terminated

All 1 trials loaded